Abstract The antinociceptive effect of caffeine was examined by using the hot-plate, abdominal constriction tests in mice and the tail flick and paw-pressure tests in rats. Caffeine (1-5 mg kg -1 s.c. in mice; 2.5-5 mg kg -1 i.p. in rats) produced significant antinociception in both species which was prevented by atropine (5 mg kg -1 i.p.), pirenzepine (0.1 µg per mouse i.c.v.), hemicholinium-3 (1 µg/ mouse i.c.v.) and N 6 -cyclopentyladenosine (5 µg/mouse i.c.v.), but not by naloxone (1 mg kg -1 i.p.), CGP 35348 (100 mg kg -1 i.p.), α-methyl p-tyrosine (100 mg kg -1 i.p.) and reserpine (2 mg kg -1 i.p.). Intracerebroventricular injection of caffeine in mice at doses (2.5-5 µg per mouse) which were largely ineffective by parenteral routes, induces an antinociception whose intensity equalled that obtainable s.c. or i.p. In the antinociceptive dose-range, caffeine did not produce any behavioural impairment as revealed by the rotarod and Irwing tests. On the basis of the above data, it can be postulated that caffeine exerts an antinociceptive effect mediated by central amplification of cholinergic transmission.
Introduction
Caffeine is the most popular psychoactive drug in the world (Max 1986 ). Many people who ingest caffeine experience various degrees of arousal characterized by reduced drowsiness and fatigue (Curatolo and Robertson 1983) . Caffeine is used as an adjuvant analgesic for various types of pain such as headache, postpartum pain, postoperative pain, dental surgery pain (Sawynok and Yaksh 1993) , in combination with non-steroidal anti-inflammatory drugs (Cass and Frederik 1962; Vinegard et al. 1976; Jain et al. 1978; Laska et al. 1984; Forbes et al. 1991; Schachtel et al. 1991; Ward et al. 1991; Sawynok and Yaksh 1993) and in combination with morphine (Person et al. 1985; Mirsa et al. 1985; Malec and Michalska 1988) . In animal studies caffeine also has intrinsic antinociceptive properties in threshold tests (Person et al. 1985; Malec and Michalska 1988; Sawynok and Reid 1996a) and in inflammatory tests (Siegers 1973; Seegers et al. 1981; .
Caffeine (50 µM) produced an enhancement of acetylcholine (ACh) release in electrically stimulated rat brain slices ) and, at 100 µM, in rat hippocampal synaptosomes (Pedata et al. 1986 ). More recently, Carter et al. (1995) showed that the oral administration of caffeine dose-dependently increased the extracellular levels of ACh, through a selective antagonism of A 1 receptors, measured by microdialysis technique in the hippocampus of freely moving rats. Furthermore, in the rat cerebral cortex, caffeine reduced the inhibition of ACh release produced by morphine (Jhamandas et al. 1978; Phillis et al. 1980) . It has long been known that ACh (Pedigo et al. 1975) , selective M 1 agonists such as McN-A-343 and AF-102B , unselective muscarinic agonists such as tremorine (Lenke 1958) , oxotremorine (George et al. 1962; Bartolini et al. 1987) , arecoline (Herz 1962), pilocarpine (Hendershot and Forsaith 1959) and cholinesterase inhibitors such as physostigmine (Harris et al. 1969; Ireson 1970 ) and diisopropyl phosphorofluoridate (Lentz et al. 1969 ) induce antinociception in laboratory animals by the activation of the cholinergic system. Moreover, the amplification of cholinergic neurotransmission induced by antagonism of muscarinic autoreceptors Gualtieri et al. 1989; Ghelardini et al. 1990) or, alternatively, by interaction with heteroreceptors ) located on presynaptic cholinergic terminals, produces a central antinociceptive effect.
Since A 1 receptors are heteroreceptors of central cholinergic neurones which exert an inhibitory control of ACh release Jackisch et al. 1984; Carter et al. 1995) , we decided to investigate the involvement of the cholinergic system in the mechanism of analgesic action of caffeine in mice and rats.
Methods
Animals. Male Swiss albino mice (23-30 g) and Wistar rats (200-300 g) from the Morini breeding farm (San Polo d'Enza, Italy) were used. Fifteen mice and four rats were housed per cage. The cages were placed in the experimental room 24 h before the test for acclimatisation. The animals were kept at 23 ± 1°C with a 12 h light/dark cicle, light at 7 a.m., with food and water ad libitum.
Drugs. The following drugs were used: caffeine, atropine sulphate, α-methyl p-tyrosine methyl ester hydrochloride and physostigmine sulphate (Sigma, USA); hemicholinium-3 hydrobromide (HC-3); pirenzepine dihydrochloride, naloxone hydrochloride and N 6 -cyclopentyladenosine (RBI); CGP 35348 (3-aminopropyl-diethoxymethyl-phosphinic acid), ascorbic acid and reserpine (Ciba Geigy, Switzerland); oxotremorine hydrochloride (Fluka); sodium chloride and acetic acid glacial (Merck).
Experimental design. Animals were randomly assigned to a control (saline solution) or a treated group (caffeine). Both groups received a pretreatment consisting of the injection of one of the following drugs: atropine, pirenzepine, naloxone, hemicholinium-3 (HC-3), CGP-35348, α-methyl p-tyrosine methyl ester, N 6 -cyclopentyladenosine or reserpine. All the drugs were injected 15 min before treatment with the exception of HC-3, CGP 35348, α-methyl p-tyrosine and reserpine. HC-3, α-methyl p-tyrosine and CGP-35348 were administered respectively 5 h, 2 h and 5 min before treatment whereas reserpine was injected twice, 48 and 24 h, before the test. All animals used were drug naive. All experiments were carried out according to the Principles of Laboratory Animal Care and the guidelines of the European Community Council. All drugs were dissolved, immediately before use, in isotonic (NaCl 0.9%) saline solution except reserpine which was dissolved respectively in a 20% solution of ascorbic acid. Drug concentrations were prepared in such a way that they could be administered in a volume of 10 ml kg -1 subcutaneously (s.c.), intraperitoneally (i.p.) and of 5 µl/mouse or 10 µl/rat intracerebroventricularly (i.c.v.).
I.c.v. administration was performed under ether anaesthesia using isotonic saline as solvent, according to the method described for mice by Haley and McCormick (1957) and extrapolated to rats by us. Substances were injected at the necessary dose dissolved in 5 µl isotonic saline solution for mice and 10 µl for rats. To ascertain the exact drug injection point, some mice or rats were injected i.c.v. with 5 or 10 µl of diluted 1:10 Indian ink and their brains were examined macroscopically after sectioning.
Hot plate test. The method adopted was described by O'Callaghan and Holtzman (1976) . Mice were placed inside a stainless steel container, thermostatically set at 52.5 ± 0.1°C in a precision waterbath from KW Mechanical Workshop, Siena, Italy. Reaction times (s), were measured with a stop-watch about 30 min before pretreatment (pretest) and 15, 30, 45, 60 and 90 min after treatment. The endpoint used was the licking of the fore or hind paws. Those mice scoring below 12 and over 18 s in the pretest were rejected (30%). An arbitrary cut-off time of 45 s was adopted at which the animals were removed from the hot-plate and given a score of 45 s.
Abdominal constriction test.
The test was performed in mice according to Koster et al. (1959) . Mice were injected i.p. with a 0.6% solution of acetic acid (10 ml kg -1 ). The number of stretching movements was counted for 10 min, starting 5 min after acetic acid injection. Caffeine was administered 5 min before acetic acid injection.
Paw pressure. The nociceptive threshold in the rat was determined with an analgesimeter (Ugo Basile, Varese, Italy), according to the method described by Leighton et al. (1988) . Threshold pressure was measured about 30 min before treatment (pretest) and 15, 30 and 45 min after treatment. Rats scoring below 50 g or over 85 g during the pretest were rejected (25%). An arbitrary cut-off value of 250 g was adopted.
Tail flick. An analgesimeter from Ugo Basile (Varese, Italy) was used to perform the tail-flick test described by D'Amour and Smith (1941) . The light from a project bulb situated beneath the platform where the animal was placed, was focused through a small hole on the ventral part of the tail at a point about 4 cm from the tip. Withdrawal of the tail exposed a photocell to the light, which turned off the thermal stimulus and automatically stopped the clock. The intensity was regulated so that the reaction time varied between 2 and 4 s. The analgesia was tested before and 15, 30 and 45 min after treatment. Each value was derived from the mean of three consecutive readings in which the light was focused on three adjacent points of the tail.
Rota-rod test. The apparatus consisted of a base platform and a rotating rod of 3 cm diameter with a non-slippery surface. This rod was placed at height of 15 cm from the base. The rod, 30 cm in length, was divided into 5 equal sections by 6 disks. Thus up to 5 mice were tested simultaneously on the apparatus, with a rod-rotating speed of 16 rpm. The integrity of motor coordination was assessed on the basis of endurance time of the animals on the rotating rod. One day before the test, the animals were trained twice. On the day of the test only the mice that were able to stay balanced on the rotating rod between 70 and 120 s (cut-off time) were selected for testing. The performance time was measured before and at various times after treatment.
Irwing test. The test was performed according to the method described by Irwing (1966) .
Statistical analysis.
Results are given as the mean ± S.E.M.; analysis of variance, followed by Scheffe's F procedure for post-hoc comparison, was used to verify the significance between two means. P values of less than 0.05 were considered significant. Data were analysed with the StatView for Macintosh (1992) computer program.
Results
The antinociceptive effect of caffeine was investigated using the hot-plate and abdominal constriction tests in mice and the tail flick and paw pressure tests in rats. In the hot-plate test caffeine, injected s.c., in the range of doses of 1-5 mg kg -1 (Fig. 1) , and i.c.v. (2.5-5 µg/ mouse) (Fig. 2) induced a significant increase in the pain threshold. The antinociceptive effect reached a maximum 15 min after administration and then diminished, disappearing within 60 min. Table 1 shows that caffeine antinociception was completely prevented by the antimuscarinic drug pirenzepine (0.1 µg/mouse i.c.v.), the choline uptake blocker HC-3 (1 µg/mouse i.c.v.) and the A 1 agonist N 6 -cyclopentyladenosine (5 µg/mouse i.c.v.). Conversely, no modification in caffeine antinociception was obtained by pretreating mice with the opioid antagonist naloxone (1 mg kg -1 i.p.), the GABA B antagonist CGP 35348 (100 mg kg -1 i.p.) and the monoamine synthesis inhibitor α-methyl p-tyrosine (100 mg kg -1 i.p.) ( Table 1 ).
The dose-response curve of caffeine administered s.c. (3-5 mg kg -1 ) in the abdominal constriction test is shown in Fig. 3 . The reduction in the number of abdominal constrictions caused by caffeine (5 mg kg -1 s.c.) was prevented by pretreatment with the antimuscarinic agent atropine (5 mg kg -1 i.p.) and HC-3 (1 µg/mouse i.c.v.), but was not modified by reserpine (2 mg kg -1 i.p.), a monoamine store depletor (Fig. 3) .
As shown in Table 2 , caffeine antinociception was confirmed in the rat paw-pressure test. Caffeine, administered i.p. at the dose of 1-5 mg kg -1 , induced antinociception, peaking after 15 min and persisting up to 30 min (Table Table 1 Effects of pirenzepine, hemicholinium-3 (HC-3), N 6 -cyclopentyladenosine (N 6 -CPA), naloxone, CGP-35348 and α-methyl-p-tyrosine (αMpT) on antinociception caused by caffeine in the mouse hot-plate test
The number of mice is shown in parentheses. * P < 0.01; ** P < 0.05 in comparison with saline-saline; *** P < 0.01 versus saline-caffeine treated mice. The number of mice ranged from 8 to 21 with the exception of saline-saline which numbered 27 Caffeine 5 15.1 ± 0.7 17.6 ± 1.5*** 16.9 ± 2.0*** 16.2 ± 1.5 HC-3 1 µg/mouse i.c.v. Saline 13.7 ± 0.5 14.8 ± 1.2 13.8 ± 1.1 13.5 ± 1.5 Caffeine 5
14.1 ± 0.8 17.8 ± 1.2*** 16.7 ± 2.1*** 16.5 ± 1.6 N 6 -CPA 5 µg/mouse i.c.v. Saline 13.9 ± 0.7 15.0 ± 0.9 15.7 ± 1.1 16.4 ± 1.7 Caffeine 5
14.3 ± 0.6 16.1 ± 1.8*** 16.5 ± 1.5*** 15.5 ± 1.2 Naloxone 1 mg kg -1 i.p. Saline 13.7 ± 0.6 14.9 ± 1.0 15.1 ± 1.3 15.2 ± 1.6 Caffeine 5
15.2 ± 0.8 26.7 ± 1.5* 21.7 ± 1.9* 20.3 ± 2.1** CGP 35348 100 mg · kg -1 Saline 13.9 ± 0.9 11.6 ± 1.1** 12.7 ± 1.7 13.1 ± 1.5 i.p.
Caffeine 5 15.1 ± 1.0 25.3 ± 1.7* 23.3 ± 2.1* 18.5 ± 1.6 α-MpT 100 mg kg -1 i.p. Saline 14.5 ± 0.7 16.7 ± 1.3 15.8 ± 2.1 15.1 ± 1.9 Caffeine 5
13.6 ± 0.9 26.4 ± 2.0* 24.5 ± 1.8* 16.8 ± 1.3
2). In the paw-pressure test, no antinociception by caffeine (5 mg kg -1 i.p.) was detected in rats pretreated with HC-3 ( Table 2 ). The analgesic profile of caffeine (2.5-5 mg kg -1 ) investigated in the tail flick test exhibited a similar antinociceptive profile to that observed in the paw pressure test (Fig. 4) . Finally, it should be noted that caffeine elicited its antinociceptive effects without changing motor coordination. Furthermore, caffeine, unlike oxotremorine and physostigmine, increased the pain threshold without causing the typical cholinergic symptomatology (Table 3) .
Discussion
Caffeine antinociception was elicited with all noxious stimuli used: thermal (hot-plate and tail flick test), chemical (abdominal constriction test) and mechanical (paw The number of rats is shown in parentheses. * P < 0.01, ** P < 0.05 in comparison with saline-saline; *** P < 0.01 versus saline-caffeine treated rat 
Saline 10 µl/rat Caffeine 1 56.9 ± 3.2 82.6 ± 4.4** 70.6 ± 4.0** 63.4 ± 3.2 (6) (6) (6) (6) Caffeine 5 58.4 ± 2.7 142.3 ± 5.4* 111.3 ± 5.4* 70.6 ± 3.2 (8)
HC-3 1 µg/rat Saline 56.4 ± 2.8 61.2 ± 4.1 62.3 ± 3.7 59.8 ± 3.4 (10) (10) (10) (10) Caffeine 5 61.3 ± 3.1 69.2 ± 4.8*** 63.5 ± 3.7*** 56.7 ± 4.2 (7) (7) (7) (7) 98.7 ± 5.4 (10) 107.6 ± 5.3 (10) 104.2 ± 5.1 (10) 95.3 ± 5.2 (10) Oxotremorine 40 µg kg -1 s.c. 101.7 ± 7.3 (15) 73.7 ± 6.6* (15) 60.2 ± 7.3* (15) 63.6 ± 7.5* (15) Physostigmine 200 µg kg -1 s.c. 95.6 ± 5.5 (13) 64.8 ± 6.1* 55.5 ± 7.2* (13) 50.6 ± 8.0* (13) pressure test). Doses which increase the pain threshold were devoid of any other modification of animal behaviour, such as motor incoordination, as demonstrated by the Irwing and rotarod tests. Caffeine antinociception was found to be dependent on cholinergic activation as this analgesia is antagonised by the muscarinic antagonists atropine and pirenzepine and by the ACh depletor HC-3. Caffeine exerts its antinociceptive effect by acting centrally since, after i.c.v. administration, it is able to increase the pain treshold with the same intensity as that obtainable after s.c. administration. The antagonism exerted by i.c.v. injected HC-3 in mice and rats on caffeine induced antinociception, shows that the site of action of caffeine is centrally located. A presynaptic mechanism facilitating cholinergic transmission is involved in caffeine antinociception as revealed by HC-3 antagonism. A postsynaptic mechanism of action can be ruled out since, as reported by Bartolini et al. (1987; , HC-3 was not able to antagonise antinociception induced by agonists of postsynaptic muscarinic receptors such as oxotremorine, McN-A-343 and AF-102B. The integrity of the central cholinergic system is, therefore, fundamental for caffeine antinociception.
A large difference exists between the analgesia induced in animals by caffeine and that induced by direct muscarinic agonists and cholinesterase inhibitors. While caffeine, like all drugs interacting with presynaptic muscarinic auto- (Ghelardini et al. 1990 ) and heteroreceptors , produces antinociception without any visible side effects, the direct muscarinic agonists and cholinesterase inhibitors provoke, at the same time, antinociception and a clear cholinergic symptomatology (tremors, sialorrhoea, diarrhoea, lacrimation etc.) .
The hypothesis of a presynaptic cholinergic mechanism for caffeine is in agreement with previous results demonstrating, by microdialysis studies, an increase in ACh release from rat hippocampus obtained through a selective interaction of caffeine with A 1 receptors (Carter et al. 1995) . Since the A 1 agonist N 6 -cyclopentyladenosine exerted a counteractive effect not only on caffeine-induced ACh release (Carter et al. 1995) , but also on caffeine antinociception, the hypothesis of a presynaptic cholinergic mechanism mediated via A 1 receptor antagonism for caffeine enhancement of the pain threshold is confirmed.
It has been shown that caffeine increases turnover of ACh (Haubrich et al. 1981; Murray et al. 1982 ) via a mechanism exerted at the level of cholinergic cell bodies (Rainnie et al. 1994) . Therefore, the activation of the cholinergic system responsible for the caffeine antinociception could be caused not only by an enhancement of the ACh release, but also by an increased ACh turnover.
The results obtained have shown a discrepancy between the antinociceptive effect of caffeine and the potentiation of cerebral ACh release described by Carter et al. (1995) . In fact, the latency required to reach the maximum ACh release (80 min) by caffeine was greater than that required to reach their antinociceptive peak (15-30 min). The greater latency required could be ascribed to the different administration routes (per os in microdialysis studies; i.p. and s.c. for antinociceptive studies). Moreover, the time taken by ACh to diffuse from the synaptic cleft to the microdialysis tube can further increase the latency required to reach the caffeine's maximum effect. The ACh release induced by caffeine was longer-lasting than its analgesic effect. It should be kept in mind that microdialysis experiments were in the presence of neostigmine which, by inhibiting the degradation of ACh, prolongs the increase of extracellular ACh due to caffeine.
Other neurotransmitter systems did not appear to be involved in caffeine antinociception since the opioid antagonist naloxone, in agreement with , the GABA B antagonist CGP 35348, α-methyl-p-tyrosine methyl ester and reserpine, were all unable to prevent a caffeine-induced analgesic effect. In contrast, Sawynok and Reid (1996b) showed that the central depletion of serotonin inhibited caffeine antinociception in the rat formalin test. In our experimental conditions, doses of caffeine about 10-fold lower than those used by Sawynok and Reid and devoid of any other behavioural effect, were employed. Therefore, we cannot exclude the involvement of the serotoninergic system in caffeine antinociception at doses at which the locomotor activity is stimulated.
The doses and administration schedules of naloxone, CGP 35348, α-methyl-p-tyrosine and reserpine were suitable for preventing antinociception induced respectively by morphine (Ghelardini et al. 1990 ), GABA B agonist baclofen (Malcangio et al. 1991) , amphetamine (Bartolini et al. 1987 ) and the antidepressant drugs clomipramine and amitriptyline (Galeotti et al. 1995) .
In summary, our results show that caffeine antinociception is induced by potentiating endogenous cholinergic activity.
